chloromethyl nonanoate | 77877-95-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: chloromethyl nonanoate
• CAS: 77877-95-3
• 化学式: C₁₀H₁₉ClO₂
• 分子量: 206.713
• InChiKey: NNVIRQBZFULPEI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  13
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-氟脲嘧啶 、 chloromethyl nonanoate 在 三乙胺 作用下， 以 吡啶 为溶剂， 以75.8%的产率得到5-fluoro-1-nonanoyloxymethyl-1H-pyrimidine-2,4-dione
  参考文献：
  名称：

  5-Fluorouracil derivatives. IV. Synthesis of antitumor-active acyloxyalkyl-5-fluorouracils.

  摘要：

  通过在 5-氟尿嘧啶（1）的 1-、3-或 1，3-位（s）上引入酰氧基烷基（s），5-氟尿嘧啶（1）的毒性和肿瘤亲和力得到了改变。1-Acyloxyalkyl-5-fluorouracil (3)、3-acyloxyalkyl-5-fluorouracil (4) 和 1，3-bis (acyloxyalkyl)-5-fluorouracil (5) 是通过以下三种方法获得的：i) α-Cloroalkyl carboxylate (2) 与 1 的反应；ii) 亚烷基二乙酸酯与 2，4-bis (trimethylsilyloxy)-5-fluoropyrimidine 的反应；iii) 5 的部分水解。化合物 3、4 和 5 具有抗肿瘤活性。

  DOI：

  10.1248/cpb.32.733
• 作为产物：
  描述：

  壬酸甲酯 在 氯 作用下， 以0.6%的产率得到chloromethyl nonanoate
  参考文献：
  名称：

  Korhonen, Ilpo O.O.; Korvola, Jorma N. J., Acta chemica Scandinavica. Series B: Organic chemistry and biochemistry, 1981, vol. 35, # 6, p. 461 - 464

  摘要：

  DOI：

文献信息

• [EN] PRODRUGS OF CGRP ANTAGONISTS<br/>[FR] PROMÉDICAMENTS D'ANTAGONISTES DU CGRP
  申请人：BIOHAVEN PHARM HOLDING CO LTD

  公开号：WO2020077038A1

  公开（公告）日：2020-04-16

  Disclosed are prodrugs of CGRP antagonists, methods of treating CGRP related disorders, e.g., migraine, by administering to a patient in need thereof the prodrugs, pharmaceutical compositions comprising prodrugs and kits including the pharmaceutical compositions and instructions for use.

  披露了CGRP拮抗剂的前药，治疗CGRP相关疾病的方法，例如偏头痛，通过向需要的患者给予前药，包含前药的药物组合物以及包括药物组合物和使用说明的工具包。
• Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient
  申请人：Maruyama Toru

  公开号：US20050020686A1

  公开（公告）日：2005-01-27

  A pharmaceutical composition for topical administration for prevention and/or treatment of diseases associated with decrease in bone mass comprising an EP 4 agonist as an active ingredient. An EP 4 agonist, in which includes a compound possessing prostaglandin skeleton as a representative, possesses promoting action on bone formation, so it is useful for prevention and/or treatment of diseases associated with decrease in bone mass (bone diseases such as primary osteoporosis, secondary osteoporosis, bone metastasis of cancer, hypercalcemia, Paget's disease, bone loss and bone necrosis, postoperative osteogenesis, alternative therapy for bone grafting).

  一种用于局部给药以预防和/或治疗与骨质减少相关的疾病的药物组合物，其包括EP4激动剂作为活性成分。EP4激动剂包括具有前列腺素骨架的化合物，具有促进骨形成的作用，因此对于预防和/或治疗与骨质减少相关的疾病（如原发性骨质疏松症、继发性骨质疏松症、骨转移性癌症、高钙血症、Paget病、骨丢失和骨坏死、术后成骨、骨移植替代疗法）非常有用。
• PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DISEASES ASSOCIATED WITH DECREASE IN BONE MASS COMPRISING EP4 AGONIST AS ACTIVE INGREDIENT
  申请人：MARUYAMA Toru

  公开号：US20100010222A1

  公开（公告）日：2010-01-14

  A pharmaceutical composition for topical administration for prevention and/or treatment of diseases associated with decrease in bone mass comprising an EP 4 agonist as an active ingredient. An EP 4 agonist, in which includes a compound possessing prostaglandin skeleton as a representative, possesses promoting action on bone formation, so it is useful for prevention and/or treatment of diseases associated with decrease in bone mass (bone diseases such as primary osteoporosis, secondary osteoporosis, bone metastasis of cancer, hypercalcemia, Paget's disease, bone loss and bone necrosis, postoperative osteogenesis, alternative therapy for bone grafting).

  一种用于局部治疗预防和/或治疗与骨量减少相关疾病的药物组合物，包括EP4激动剂作为活性成分。EP4激动剂，其中包括具有前列腺素骨架的化合物作为代表，具有促进骨形成的作用，因此对于预防和/或治疗与骨量减少相关的疾病（如原发性骨质疏松症、继发性骨质疏松症、骨癌转移、高钙血症、帕吉特病、骨丢失和骨坏死、术后骨生成、骨移植替代疗法）非常有用。
• REMEDIES FOR DISEASES WITH BONE MASS LOSS HAVING EP sb 4 /sb AGONIST AS THE ACTIVE INGREDIENT
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1417975A1

  公开（公告）日：2004-05-12

  A pharmaceutical composition for topical administration for prevention and/or treatment of diseases associated with decrease in bone mass comprising an EP4 agonist as an active ingredient. An EP4 agonist, in which includes a compound possessing prostaglandin skeleton as a representative, possesses promoting action on bone formation, so it is useful for prevention and/or treatment of diseases associated with decrease in bone mass (bone diseases such as primary osteoporosis, secondary osteoporosis, bone metastasis of cancer, hypercalcemia, Paget's disease, bone loss and bone necrosis, postoperative osteogenesis, alternative therapy for bone grafting).

  一种局部用药的药物组合物，用于预防和/或治疗与骨量减少有关的疾病，其活性成分包括一种 EP4 激动剂。EP4激动剂（其中包括以前列腺素骨架为代表的化合物）具有促进骨形成的作用，因此可用于预防和/或治疗与骨量减少有关的疾病（骨病，如原发性骨质疏松症、继发性骨质疏松症、癌症骨转移、高钙血症、Paget病、骨丢失和骨坏死、术后成骨、植骨替代疗法）。
• Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as active ingredient
  申请人：Ono Pharmaceutical Co., Ltd.

  公开号：EP2255829A2

  公开（公告）日：2010-12-01

  A pharmaceutical composition for topical administration for prevention and/or treatment of diseases associated with decrease in bone mass comprising an EP4 agonist as an active ingredient. An EP4 agonist, in which includes a compound possessing prostaglandin skeleton as a representative, possesses promoting action on bone formation, so it is useful for prevention and/or treatment of diseases associated with decrease in bone mass (bone diseases such as primary osteoporosis, secondary osteoporosis, bone metastasis of cancer, hypercalcemia, Paget's disease, bone loss and bone necrosis, postoperative osteogenesis, alternative therapy for bone grafting).

  一种局部用药的药物组合物，用于预防和/或治疗与骨量减少有关的疾病，其活性成分包括一种 EP4 激动剂。EP4激动剂（其中包括以前列腺素骨架为代表的化合物）具有促进骨形成的作用，因此可用于预防和/或治疗与骨量减少有关的疾病（骨病，如原发性骨质疏松症、继发性骨质疏松症、癌症骨转移、高钙血症、Paget病、骨丢失和骨坏死、术后成骨、植骨替代疗法）。

表征谱图